All News
EMA Crack Down on JAK Inhibitors
The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.
Read Article
Infections & Lupus (10.28.2022)
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
Read Article
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR2022 meeting in Philadelphia.
https://t.co/yCMStA8yQm https://t.co/myS0sT9BMq
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow #ACR2022 Reporter Spotlight: Dr. Richard Conway
What are you most looking forward to this year at ACR?
Dr. Conway: "I'm looking forward to experiencing the enhanced virtual offering this year."
Follow him at @RichardPAConway for more ACR RheumNow coverage! https://t.co/xwl8Jqn1Yf
Dr. John Cush RheumNow ( View Tweet)
Chest CT Airway Dz compared betw GPA (n26) & relapsing polychondritis (n19). Subglottic involvement favors GPA (OR 28.6) & Extensive airway Dz favor of RP (GP OR 0.02). Lesser RP assoc w/ Posterior tracheal sparing & tracheal calcifications. https://t.co/TaaEjpPm76 https://t.co/mwljLYIymH
Links:
Dr. John Cush RheumNow ( View Tweet)
Increasing Risk of Lupus Nephritis
A population based study shows that LN in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates 6x that of the general population.
https://t.co/aBSUP9ExTh https://t.co/RfgSH0wmOu
Links:
Dr. John Cush RheumNow ( View Tweet)
Update to Axial Spondyloarthritis Guidance
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
https://t.co/iAUXrVp1P3 https://t.co/bHwjI6xJUq
Links:
Dr. John Cush RheumNow ( View Tweet)
New ACR/EULAR Guideline Expands RA Remission Definition
Newly released guidance for defining remission in RA is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
https://t.co/ZZN3kAGW8F https://t.co/iaYUvxYHMq
Links:
Dr. John Cush RheumNow ( View Tweet)
PSOAS study of 354 with long-standing ankylosing spondylitis & SI radiographic changes; but 23 lacked syndesmophytes. Lack of fusion was more likely in women & w/younger age of Sx onset. All were B27+, thus B27 may be assoc w/ SI dz, not spinal dz. https://t.co/QCyTCHjK6u https://t.co/gT3tFuZCDq
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 ASAS-EULAR Guidelines for Axial Spondyloarthritis
Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).
https://t.co/YI3ZKfaU9k https://t.co/4bbETabYaf
Links:
Dr. John Cush RheumNow ( View Tweet)
Mayo Clinic Biobank matched case-control study (1:3) of 212 incident RA cases Active work physical activity lowered risk of RA (aOR 3.00), while 3-5 servings high-fat foods, fruits/vegetables lowered risk (OR 0.45; OR 0.54). https://t.co/PW6XRxzcDi https://t.co/wXnu9T55Yb
Links:
Dr. John Cush RheumNow ( View Tweet)
TNF inhibitors Dont Increase Cancer Risk! 4592 RA pts:TNFi Rx (2296) vs matched DMARD Rx (2296) pts. TNFi had a lower cancer risk than DMARD Rx (IR 6.5 vs. 15.6 /1000PYs]). TNFi had Lower HR GI CA (0.432), breast CA (0.146), GU CA (0.220) https://t.co/mf1g0LwjXR
Dr. John Cush RheumNow ( View Tweet)
Predictors of serious infection (SIE) in SLE? A prior SIE conferred the highest risk of subsequent SIE. Study of 346 SLE pts shows SIE rate of 3.8/100 Pt-Yrs. Other risk factors:
Damage accrual, comorbidity, Dz activity, CTX use https://t.co/hvAtpTUPml https://t.co/QkJp7ssOUU
Links:
Dr. John Cush RheumNow ( View Tweet)
Celebrating my 10,000 followers on TikTok. @Rheum101 is where I make videos teaching rheumatology to the general public in 3 min bites. Topics include #SLE #Steroids #RA #ANA #RheumLabs #DMARDS #biologics #JAKi #osteoporosis #PsA and more #RheumEducation #NotMedicalAdvice https://t.co/WEXspp5v28
TheDaoIndex KDAO2011 ( View Tweet)
Hematoinflammatory diseases https://t.co/3Xd76ab7yP
Luis Caminal caminalm ( View Tweet)
⏫IgG4 🚫 IgG4 RD
Elevated IgG4 levels can be seen:
👉 Chronic infections like #tuberculosis
👉Lymphoproliferative malignancies
👉 Bronchiectasis, #asthma
👉 Primary sclerosing cholangitis
#RheumTwitter #MedTwitter #Rheumatology https://t.co/N3EDYjyFLf
Pankti Mehta PanktiMehta24 ( View Tweet)
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
https://t.co/cpOTUsok7e https://t.co/5Ew7Hr9Mcd
Links:
Dr. John Cush RheumNow ( View Tweet)
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR2022 meeting in Philadelphia.
https://t.co/0DOBvpsV6r https://t.co/T8VrFlu6xq
Links:
Dr. John Cush RheumNow ( View Tweet)
CONGRATS to Dr Jean Liew: from Bronte scholar to social media influencer https://t.co/f9ZrvxaPgB
Dr. John Cush RheumNow ( View Tweet)
RA is an independent risk factor for Thyroid Dz & AITD. Study of 250 RA & 248 non-inflammatory RMD controls. RA had more abnl TFTs (34% v 19%; OR 2.2), Overt hypothyroidism, Anti-TPO Abs, & AITD (21.5% vs 9%; OR 2.8). https://t.co/lRvY4VGkUc https://t.co/ibUqPiD9Bv
Links:
Dr. John Cush RheumNow ( View Tweet)